|
Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing head and neck tumors: Outcomes from DESTINY-PanTumor02 (DP-02). |
|
|
Employment - MD Anderson Cancer Center |
Honoraria - Dava Oncology |
Consulting or Advisory Role - Abbvie; AstraZeneca; Black Diamond Therapeutics; Calibr; Daiichi Sankyo/Astra Zeneca; EcoR1 Capital; Eisai; Exelixis; GT Aperion; Incyte; Infinity Pharmaceuticals; Karyopharm Therapeutics; LegoChem Biosciences; Lengo Therapeutics; Menarini Group; OnCusp Therapeutics; Protai; Seagen; Tallac Therapeutics; Theratechnologies; Zentalis; Zymeworks |
Research Funding - Abbvie (Inst); Aileron Therapeutics (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Calithera Biosciences (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Debiopharm Group (Inst); eFFECTOR Therapeutics (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Guardant Health (Inst); Jazz Pharmaceuticals (Inst); Klus Pharma (Inst); Novartis (Inst); Pfizer (Inst); PUMA Biotechnology (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Zymeworks (Inst) |
Travel, Accommodations, Expenses - ARTIDIS; Cholangiocarcinoma Foundation; Dava Oncology; ESMO; European Organisation for Research and Treatment of Cancer (EORTC) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Travel, Accommodations, Expenses - PharmaMar; Roche |
|
|
Honoraria - Daiichi Sankyo; Lilly; Novartis; Novartis; Roche |
Consulting or Advisory Role - Abbvie; Anbogen Therapeutics; Bayer; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; IMPAC Medical Systems; Novartis; PharmaEngine |
Travel, Accommodations, Expenses - BeiGene; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; IMPAC Medical Systems; Lilly |
|
|
Employment - Hadassah Medical Ltd; Medscan Joint Stock Company |
Honoraria - Berlin-Chemie; Menarini LLC |
|
|
Honoraria - AstraZeneca; Eisai |
|
|
Honoraria - Agenus; Amgen; AstraZeneca; BeiGene; BMS; Celon Pharma; Cullinan Oncology; Jacobio; Janssen; Loxo; Macrogenics; Menarini; MSD; Pfizer; Rhizen Pharmaceuticals; ROCHE; Sanofi; Sanofi; Takeda |
Consulting or Advisory Role - Boehringer Ingelheim |
Research Funding - AGENUS (Inst); ROCHE (Inst) |
Travel, Accommodations, Expenses - BMS |
|
|
Speakers' Bureau - AstraZeneca; BioCad; Bristol-Myers Squibb; Roche/Genentech |
Travel, Accommodations, Expenses - AstraZeneca; Novartis; Roche; Roche |
|
|
Consulting or Advisory Role - BMS; MSD Oncology; Roche |
Speakers' Bureau - AstraZeneca; Novartis; Pfizer; Roche |
Travel, Accommodations, Expenses - Takeda |
|
|
Stock and Other Ownership Interests - CSL Limited (I) |
|
|
Consulting or Advisory Role - PredOmix Technologies Pvt (Inst) |
Research Funding - BDR Pharmaceutics (Inst); Cadila Pharmaceuticals (Inst); Dr. Reddy's Laboratories (Inst); Intas (Inst); Lupin Pharmaceuticals (Inst); NATCO Pharma (Inst); Panacea Pharmaceuticals (Inst); Panacea Pharmaceuticals (Inst) |
Travel, Accommodations, Expenses - AstraZeneca; Intas; NATCO Pharma; NATCO Pharma; PredOmix Technologies Pvt |
|
|
|
|
|
|
Stock and Other Ownership Interests - AstraZeneca |
Research Funding - AstraZeneca |
Travel, Accommodations, Expenses - AstraZeneca |
|
Nataliya Kuptsova-Clarkson |
|
Stock and Other Ownership Interests - AstraZeneca |
|
|
|
Stock and Other Ownership Interests - AstraZeneca |
Research Funding - AstraZeneca |
Travel, Accommodations, Expenses - AstraZeneca |
|
|
Consulting or Advisory Role - Curis; Merck Serono; SERVIER; Telix Pharmaceuticals |